Overview
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
Status:
Completed
Completed
Trial end date:
2016-03-02
2016-03-02
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg [three 100 mg tablets] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction [MI], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaTreatments:
Aspirin
Ticagrelor
Criteria
Inclusion Criteria:- Men or women equal or elder 40 years of age
- Either acute ischaemic stroke or high-risk TIA as defined here and randomisation
occurring within 24 hours after onset of symptoms
Key Exclusion Criteria:
- Planned use of antithrombotic therapy in addition to study medication including
antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine,
prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral
thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated
and low molecular weight heparins). - Any history of atrial fibrillation, ventricular
aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid,
cerebrovascular, or coronary revascularisation that requires halting study medication
within 7 days of randomisation. - Receipt of any intravenous or intra-arterial
thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation -
History of previous symptomatic non-traumatic intracerebral bleed at any time
(asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past
6 months, or major surgery within 30 days.